In an attempt to exhibit the benefits of 3D mammography
(breast tomosynthesis) over conventional 2D mammography,
) has planned to carry its 3D mammography in a new mobile
mammography coach for a 12 month trip. Accordingly, this leading
provider of healthcare products for women formed an alliance with
healthcare specialty vehicles provider Armor Mobile.
As per the plan, this mobile coach will traverse the U.S. in
the next one year. With this new approach, the company plans to
show how the combination of 2D and 3D in breast cancer screening
helps improve early detection, reduces false positives and
unnecessary call backs by 40% compared to 2D mammography.
We note that unlike a 2D mammogram screening that involves a
single X-ray image of the breast, 3D mammography captures
multiple, low-dose images from various angles around the breast.
The images are then used to produce a 3D digital reconstruction
of the breast.
Hologic is also scheduled to exhibit some of its newest
offerings at the annual meeting of the European Society of
Radiology, during Mar 7-11, in Vienna, Austria. The European
Congress of Radiology ("ECR"), the largest radiological meeting
in Europe, offers the ideal platform for the company to showcase
Hologic will display its extensive suite of healthcare
solutions for the screening and diagnosis of breast cancer,
breast biopsy, osteoporosis risk assessment, medical MRI coils
and extremity imaging. Management is enthusiastic about its
breast tomosynthesis program including the introduction of a
tomosynthesis biopsy option for the company's Affirm breast
biopsy guidance system. Hologic will also conduct education
sessions and training workshops for tomosynthesis-guided breast
Moreover, Hologic is set to display two new products at ECR,
namely Selenia Dimensions Avia Package and Flouroscan InSight-FD
Mini C-arm. While the Avia Package provides cost effective 2D
screening and diagnostic solutions, the Mini C-arm will meet the
needs of orthopedic and extremity surgeons by improving workspace
access and ease of positioning.
We note that expectations from the breast tomosynthesis
technology are sky-high. However, over the past few quarters,
Hologic witnessed several challenges in the form of economic
uncertainties in Europe, slower sales cycles and increasing
In the light of these facts, the estimates for the ongoing
fiscal have remained stagnant over the last 90 days. Accordingly,
the stock carries a Zacks Rank #3 (Hold). While we remain on the
sidelines for Hologic, other medical stocks such as
), each carrying a Zacks Rank #1 (Strong Buy) are expected to do
CYBERONICS INC (CYBX): Free Stock Analysis
GIVEN IMAGING (GIVN): Free Stock Analysis
HOLOGIC INC (HOLX): Free Stock Analysis
MEDICAL ACTION (MDCI): Free Stock Analysis
To read this article on Zacks.com click here.